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Abstract
Aims—Activation of PPARγ by pioglitazone (PIO) has shown some efficacy in attenuating 
addictive-like responses in laboratory animals. The ability of PIO to alter the effects of opioids in 
humans has not been characterized in a controlled laboratory setting. The proposed investigation 
sought to examine the effects of PIO on the subjective, analgesic, physiological and cognitive 
effects of oxycodone (OXY).
Methods—During this investigation, nondependent prescription opioid abusers (N=17 
completers) were maintained for 2–3 weeks on ascending daily doses of PIO (0 mg, 15 mg, 45 
mg) prior to completing a laboratory session assessing the aforementioned effects of OXY [using a 
within-session cumulative dosing procedure (0, 10, and 20 mg, cumulative dose = 30 mg)].
Results—OXY produced typical mu opioid agonist effects: miosis, decreased pain perception, 
and decreased respiratory rate. OXY also produced dose-dependent increases in positive subjective 
responses. Yet, ratings such as: drug “liking,” “high,” and “good drug effect,” were not 
significantly altered as a function of PIO maintenance dose.
Discussion—These data suggest that PIO may not be useful for reducing the abuse liability of 
OXY. These data were obtained with a sample of nondependent opioid users and therefore may not 
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be applicable to dependent populations or to other opioids. Although PIO failed to alter the abuse 
liability of OXY, the interaction between glia and opioid receptors is not well understood so the 
possibility remains that medications that interact with glia in other ways may show more promise.
Introduction
Until recently, the abuse liability of opioids was thought to be mediated primarily through 
neuronal processes. However, emerging evidence indicates that immunocompetent cells 
(glia) may contribute significantly to opioid pharmacology. Glial cells constitute over 50% 
of the cells in the central nervous system [CNS (1)]. Once thought to be the passive “glue” 
that fills the space between neurons, it is now recognized that glia play key roles in many 
neuronal processes and disease states (2, 3, 4, 5).
Research on the interaction between opioids and glia began over 30 years ago (6). Although 
this research has revealed that immune cells express opioid receptors and the mRNA to 
produce them, there remains vigorous debate over how opioids affect glia (7, 8, 9). Opioid 
use typically increases vulnerability to infection, suggesting that opioids are 
immunosuppressive (10). Much of the laboratory research seeking to investigate this 
hypothesis has examined the effects of the prototypic opioid, morphine. Several studies have 
shown that acute or chronic morphine exposure suppresses antibody response (11), 
macrophage activity (12), B-cell activity (13), T-cell activity and cytokine release (14; see 
also 15 & 16 for reviews).
Alternatively, it has been shown that opioids cause direct glial cell activation in a non-
classical opioid receptor fashion, possibly via opioid-induced activation of a class of pattern 
recognition receptors referred to as toll-like receptors (17). For example, chronic morphine 
administration has been associated with an increase in proinflammatory cytokine protein 
and/or mRNA (18), glial fibrillary acid protein (19, 20), and proliferation (astrogliosis) and 
migration of astrocytes (21, 22, 23, 24, 25).
Although the cause of these discrepant findings is still under debate, investigators have 
begun to study opioid and glial interactions as a means to separate the beneficial effects of 
opioids (analgesia) from their detrimental effects (abuse potential). Preclinical research into 
the behavioral effects of opioid-glia interactions has found that selectively increasing glial 
(astrocyte) activity in the NAcc and intracingulate cortex results in significantly greater 
preference for morphine-associated cues relative to vehicle-associated cues [morphine-
induced conditioned place preference (CPP)]. Investigators were able to attenuate this effect 
with a glial activity inhibitor (26).
As a logical extension of this work, there is a growing body of literature examining whether 
pharmacological modulators of glial cells may show some clinical utility to reduce the abuse 
potential of opioids (see reference 26 for a review). Ibudilast (AV411), minocycline, 
pentoxifylline and propentofylline are medications that suppress opioid-induced increases in 
immune factors (27, 28, 29). Furthermore, these glial modulators are hypothesized to 
decrease the rewarding effects of opioids. Ibudilast co-administered with morphine 
significantly reduced the magnitude of opioid-induced dopamine release in the NAcc (30), 
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and ibudilast, propentofylline, and minocycline reduce or completely block opioid-induced 
CPP (17, 26, 3).
Another glial modulator being investigated in this respect is the peroxisome proliferator-
activated gamma receptor (PPARγ) agonist, pioglitazone (or Actos). In the central nervous 
system, PPARs are expressed in neurons, oligodendrocytes, and astrocytes (32, 33, 34, 35). 
PPARγ agonists have been shown to inhibit the expression of cytokines by monocytes/
macrophages and microglia (36). Preclinical research further showed that PPARγ activation 
by pioglitazone (PIO) attenuated development of opioid tolerance (38) reduced heroin self-
administration under a fixed-ratio and progressive-ratio schedule of reinforcement and 
heroin-induced increases in extracellular dopamine in the nucleus accumbens (39).
The ability of PIO to alter the effects of opioids in humans has not been characterized in 
controlled, clinical laboratory settings. As such, the primary aim of the current study was to 
examine the subjective effects of oxycodone (OXY) under maintenance on various doses of 
PIO [0 (placebo), 15, and 45 mg] in nondependent, prescription opioid abusers. Oxycodone 
was chosen because it is one of the most commonly prescribed and abused opioid analgesics 
(40, 41, 42). The PIO doses employed in this study are currently used clinically for the 
treatment of insulin resistance and type 2 diabetes (43, 44). The secondary aims of the study 
were to examine the influence of PIO on the analgesic, cognitive, and physiological effects 
of OXY. Based on preclinical evidence, we hypothesized that pioglitazone would decrease 
the positive subjective effects of oxycodone while potentiating its analgesic properties. If 
this hypothesis is supported, regulation of PPARγ may represent a new pharmacotherapeutic 
strategy to reduce the abuse of opioid drugs.
Methods
Participant Screening and Selection
Participants were recruited from the New York City metropolitan area through various print 
media advertisements. Respondents who met study inclusion/exclusion criteria, based upon 
the initial telephone interview, were scheduled to come to the New York State Psychiatric 
Institute for additional screening procedures. Screening consisted of both self-report and 
clinical interviews administered by a team of research assistants, psychologists, nurses, and 
physicians. Assessments were made of drug use, general health, and medical history, and 
multiple laboratory tests (hematology, blood chemistry panel, liver and thyroid functioning, 
urinalysis, and syphilis serology) were performed. Rapid urine drug screens assessed recent 
use of opioids, cocaine, benzodiazepines, cannabinoids, and amphetamines. Naloxone (0.2–
0.8 mg) was administered intramuscularly during screening to determine if individuals were 
currently physiologically dependent on opioids.
Participants were required to be physically and mentally healthy recreational users of 
prescription opioids between the ages of 21 and 55 years. Potential participants were 
excluded from the study if they were seeking treatment for their drug use, had chronic pain, 
or had a severe Axis I psychiatric diagnosis. Potential participants were also excluded if they 
were physiologically dependent on opioids, alcohol or illicit drugs, with the presence of 
physiological withdrawal used as the principal criterion. As compensation, participants were 
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paid $25/day with a $25/day bonus for completing the study. All study procedures were 
approved by the Institutional Review Board of the New York State Psychiatric Institute 
(study # 6106).
Study Design
This within-subjects investigation was placebo-controlled and conducted under single-blind 
conditions. Participants who passed the physiological and psychological screening were 
maintained on PIO (or placebo) throughout the ≈7–9 week study. For approximately 2–3 
weeks participants were stabilized on each dose of PIO (0, 15, 45 mg) in ascending order. At 
the end of each maintenance period, the subjective, analgesic, physiological and cognitive 
effects of oral OXY (0 mg, 10, mg, 20 mg = cumulative dose of 30 mg) were examined. 
Cumulative dosing of opioids has been demonstrated to be an efficient and reliable strategy 
for assessing dose response within a single session. Data have also shown that cumulative 
opioid challenge drug dosing, conducted over time, produces reliable results with no 
evidence of habitation (45, 46, 47, 48, 49).
In its current clinical indications (diabetes mellitus type 2 and non-alcoholic steatohepatitis) 
a PIO effect typically takes 2 weeks to be observed (50). The dose order of PIO was not 
randomized due to the possibility of PIO carryover effects among the conditions. Although 
the current design also allows for the possibility of carryover effects, in this case they would 
have increased our likelihood of seeing a signal of PIO’s effects. As the first clinical 
investigation into this drug for this indication, the investigators thought the latter was more 
important. The study was conducted on an outpatient basis with participants making 3–5 
daily visits per week to the New York State Psychiatric Institute to receive study medication 
(administered and observed by a research nurse), provide a urine sample, and complete 
various study questionnaires (described below). Laboratory tests for blood glucose, liver 
function, and complete blood count, were performed weekly. Participants were provided 
with take-home PIO doses over the weekend, with pill counts and compliance assessments 
performed at each study visit. On the day of the lab session, participants were required to 
have not used alcohol recently (confirmed by breathalyzer) and provide a negative drug 
urine toxicology (Utox) the day of the lab session. Some exceptions were made for 
marijuana, because it remains detectable in the urine for such a long duration, as long as the 
reported use was not recent (within 2 days) based on self-report, and the participant 
appeared not to be acutely intoxicated. No other exceptions were made, and no lab sessions 
needed to be rescheduled due to the presence of other drugs of abuse.
The subjective effects of OXY (cumulative dose of 30 mg) were tested under each PIO 
maintenance condition. The daily maintenance dose of PIO was given on the day of the 
session 45 min prior to the OXY challenge doses (Table 1). Laboratory sessions typically 
began at 1000 hrs and took approximately 5–6 hours to complete. After the lab session, 
participants completed a field sobriety test and were sent home via a taxi or car service.
Maintenance Phase Monitoring and Measures
During each outpatient visit, participants met with a research assistant and a nurse for study 
medication dispensing and monitoring (described below). Participants completed a number 
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of assessments of: general health, PIO side effects, and outpatient drug use. Participants 
generally completed 3–5 study visits per week. Participants were given take-home doses 
over the weekends, and for days that they did not appear at NYSPI for an outpatient visit. 
Participants were instructed to bring all of their study medication to each outpatient visit so 
that pill counts could be conducted by a research nurse in order to evaluate medication 
compliance.
Adverse medication effects were assessed at each visit using the SAFTEE (51). The 
SAFTEE queries participants concerning up to 30 possible adverse events (e.g., fever, gas, 
insomnia, palpitations, dry mouth, etc. …) and rates their: severity (1=mild, 2=moderate, 
3=severe), relationship to study medication, any action taken by medical staff, and outcome. 
At each visit nurses also measured body weight, and drew blood weekly for blood chemistry 
(LFT, CBC, blood glucose, and BMP). After meeting with the nurse, participants provided a 
urine sample for 11-panel DrugCheck® urine dipstick analysis (w/pregnancy test). They also 
competed the Alcohol Use Disorders Identification Test (AUDIT-C) to assess alcohol use 
during the preceding week (52), a locally derived assessment of the type and frequency of 
other recreational drug use, and assessment of drug craving (opioids, alcohol, marijuana and 
tobacco) from ‘Not at all’ (0 mm) to ‘Extremely’ (100 mm).
Laboratory Session Measures
Subjective Effects—Two questionnaires were used to assess subjective drug effects and 
opioid withdrawal symptoms. A Visual Analog Scale (VAS) was used to assess subjective 
and physiological drug effects such as “I feel a good drug effect” and “I feel high”. 
Participants rated each item on the scale from ‘Not at all’ (0 mm) to ‘Extremely’ (100 mm). 
The second questionnaire was a modification of the Single Dose Questionnaire, which 
assessed for the presence of a number of potential drug effects by indicating “1” for True, or 
“2” for False (53, 54).
Analgesic Effects—The analgesic effects of OXY were evaluated with experimentally 
induced pain using the cold pressor test (CPT), a commonly used and well-established 
model for producing pain (55). Crushed ice was added to a cold tank, and warm water was 
placed in a warm tank. The temperature was maintained at 4°C in the cold tank (additional 
ice was added, if necessary) and 37°C in the warm tank. Each participant was asked first to 
immerse the hand in the warm tank for 2 min (to equalize baseline skin temperature across 
participants). Next, they were asked to immerse the same hand in the cold tank for up to 2 
min. Standard instructions were read to each participant before administration of the CPT. 
During the cold water immersion, subjective ratings of pain were measured. Immediately 
following the CPT, subjective ratings of pain again were measured using the MPQ (CPT-
MPQ) and the Pain Intensity/Bothersome Scales (‘Not at all’ (0) to ‘Extremely’ (10)) during 
which participants were asked to rate the ‘Intensity’ and ‘Bothersomeness’ of the acute pain 
experienced during immersion in cold (4°C) water during the CPT. Objective dependent 
measures included: pain threshold (time in seconds to the first report of pain) and pain 
tolerance (time until removal of the hand from water).
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Physiological Measures—Miosis was assessed as a physiological indicator of mu 
agonist effects using a NeurOptics™ Pupillometer (Neuroptics INC. Irvine, CA) under 
ambient lighting conditions. For safety, a pulse oximeter continuously monitored oxygen 
saturation (%SpO2) during sessions, while respiration (breaths per minute), heart rate, and 
blood pressure (systolic and diastolic) were measured and recorded every 5 minutes. 
Supplemental oxygen was also provided throughout the session.
Pharmacokinetic Measures—Oxycodone plasma concentrations (ng/ml) were assessed 
throughout the lab session (Table 1). Blood (≈8 ml/sample) was collected from an 
intravenous catheter into tubes containing 15% EDTA and centrifuged. Blood samples 
collected at +165 minutes post PIO dosing were used to assess PIO levels. Plasma was 
separated from blood and frozen at −70°C. Frozen plasma samples were batched and 
transferred to the Analytical Psychopharmacology Laboratories at the Nathan Kline Institute 
for analysis.
Drugs
Pioglitazone tablets (15 mg) were provided by the OMEROS Corporation (Seattle, WA). 
Each daily dose consisted of 3 capsules of active drug and/or lactose-filled placebo, 
depending on the final target dose (e.g. 45 mg = 3 ∘ 15 mg tablets; 15 mg = 1 ∘ 15 mg tablet 
+ 2 placebo tablets; 0 mg = 3 placebo tablets). During weekly study visits, the 3 tablets were 
administered to participants by a research nurse. For weekend dosing, participants were 
provided with a separate bottle that contained the 3 tablets for each day. Back-up doses were 
also provided in this manner, in case participants missed a study visit. All drug over-
encapsulation and packaging was performed by the New York State Psychiatric Institute 
Pharmacy.
Oxycodone HCL tablets (5 mg) were purchased from TYCO Healthcare (Princeton, NJ). 
For blinding, tablets were over-encapsulated and participants were given 4 capsules 
consisting of active drug and/or lactose-filled placebo.
Naloxone HCl (Narcan) for IM injection was obtained from the International Medication 
System Limited Amphastar (South Elmonte, CA).
Statistical Analyses
Continuous and categorical demographic variables and adverse events reports were 
summarized descriptively. Regarding data collected during the maintenance phases, 
univariate analyses of variance (ANOVA) tests were employed to examine changes in drug 
use and drug craving as a function of PIO maintenance dose (summed across each of the 3 
periods). When analyzing the data from the lab sessions, a repeated-measures ANOVA was 
used to compare the time course of drug effects over the various time points throughout the 
session for each of the PIO maintenance doses (Main effects: PIO Dose & Time). Because 
of the cumulative dosing procedure, this analysis allowed the investigators to evaluate the 
overall influence of PIO on the effects of the cumulative OXY dose (30 mg). In order to 
examine the effects of PIO on each individual OXY (0, 10, 30 mg) dose, planned 
comparisons were used to assess maximal drug effect (peak=increase or trough=decrease) 
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within the timeframe immediately prior to the next oxycodone administration. These 
planned comparisons of PIO dose failed to reveal any significant effects, and thus, for the 
sake of brevity were not included in this report. An α of p<0.05 was considered statistically 
significant, while p<0.10, was considered as trending towards significance. All data analyses 
were performed using SPSS version 18 (56) and SuperANOVA (57).
Results
Participants
Between October, 2010 and August, 2013, 32 participants were enrolled into the study. 
Fifteen participants either voluntarily withdrew from the study or were dropped by the 
investigators due to a number of factors including: elevated liver function tests (n = 1), 
vasovagal episode during the lab session (n = 2), becoming opioid dependent during 
outpatient phase (n = 1), pulmonary embolism (n = 1, determined to be unrelated to the 
study), difficulty interacting with staff (n = 1), missing too many outpatient visits (n = 7) and 
misrepresenting age or drug use history (n = 2). Complete data sets were obtained from 17 
participants for inclusion in this analysis. The average age of the participants was 35.0 years 
(± 9.0), including 15 men and 2 women. The racial breakdown of the completers was as 
follows: 8 African-American /Black, 4 Caucasian/White, 3 Multiracial, 1 Native-American 
or Alaskan, 1 not reported). Ethnically, 5 of the 17 completers considered themselves to be 
Hispanic/Latino.
All participants had recent histories of recreational use of Rx opioids (within the last year). 
The majority of participants used Rx opioids on a “Weekly” basis (n = 9), followed by 
“Monthly” use (n = 4), “Less than Monthly” (n = 3) and daily (n = 1, opioid use may have 
been over reported, since naloxone challenge indicated the participant was not 
physiologically dependent). All participants abused Rx opioids orally, with the exception of 
2 who used via oral and intranasal routes. The mean duration of recreational opioid use was 
4.1 years (± 3.5). In addition to their opioid use, 70% (n = 12) of the participants reported 
occasional alcohol use (weekly-monthly, ave 4.4 drinks/month), 56% (n = 9) were regular 
marijuana users (4 daily, 2 weekly, 3 monthly), 41% (n = 7) were regular tobacco smokers 
(daily-weekly use), and 30% used stimulants (cocaine or amphetamines) sporadically 
(monthly or less). The use of heroin, sedatives (benzodiazepines or barbiturates), club drugs 
(ecstasy, GHB, ketamine) and hallucinogens (LSD or PCP) was rare among this sample.
Maintenance Phase Measures
Prior to completing the OXY challenge testing, participants were maintained on PIO 0 mg 
for an average of 14.4 days (± 3.1), PIO 15 mg for 16.2 days (± 2.8) and PIO 45 mg for 15.6 
days (± 3.2). Variability in dosing duration was the result of accommodation for scheduling 
(e.g., holidays and weekends) and participant variables (e.g., availability for scheduling 
sessions). The adverse events judged to be “possibly” related to the study medication and 
reported by multiple participants were: GI upset, gas, fatigue and drowsiness. The severity of 
these symptoms was rated as “mild to moderate.” Adverse effects reported less regularly 
included chills and sweating. During the maintenance phases, mean VAS ratings for “I Want: 
Opioids, Alcohol, Marijuana and Tobacco,” failed to significantly differ as a function of PIO 
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maintenance dose (Table 2). Additionally, the number of positive drug UTox samples and 
breathalyzer tests did not differ significantly across the three PIO maintenance phases.
Lab Session Measures
Positive Subjective Effects—VAS assessments of positive subjective effects including: 
“Liked the Choice (Figure 1: Upper Panel),” “High,” “Good Effect,” “Quality,” 
“Stimulated,” and amount participants “Would Pay” for the drug, increased as a function of 
Time (p’s < 0.001). For all measures, the maximal drug effect was observed between 180 
and 210 minutes (i.e. ratings increased as a function of increasing OXY dose). For none of 
these measures was there a significant main effect of PIO dose, and no PIO X Time 
interaction. This same pattern of results was found for the ARCI measures of: “I Feel:” 
“High,” “Relaxed,” and “Drunken,” (Time, p’s < 0.05), and again with the more general 
indicators of drug effect, VAS “Potent,” and “Sedated” (p’s < 0.001).
Negative Subjective Effects—VAS ratings of “Irritable” significantly increased later in 
the session (Time, p< 0.01). In contrast, VAS ratings of overall “Bad Drug Effect” were 
minimal throughout the laboratory session, although the main effect of Time did approach 
significance (p = 0.07, shown in Figure 1: Lower Panel). ARCI ratings of “I Feel Nervous” 
did not significantly vary as a function of Time or PIO dose. None of these ratings varied as 
a function of PIO maintenance dose and no interaction was found. Significant drug effects 
were found on subjective measures of gastrointestinal (GI) upset. ARCI measures of 
“Turning Stomach,” and VAS assessment of “Nauseous” increased as the session progressed 
(Time, p’s < 0.001). Again, no effect of PIO or interaction was found on these measures.
Other Drug Effects—Assessments of: “Mellow,” “Restless,” and “Sleepy,” increased as a 
function of Time (p < 0.001, p <0.01, & p < 0.001; respectively) but there were no 
significant main effects of PIO dose, and no PIO X Time interactions. There were no 
significant findings (Time, PIO, PIO X Time) on assessments of: “Alert,” “Anxious,” 
“Depressed,” “Energetic,” “Gooseflesh,” “Muscle Pain,” or “Talkative.”
Experimental pain/CPT—ANOVA revealed that as the laboratory session progressed 
(and the OXY dose increased) there were significant increases in the analgesic effects of 
oxycodone. Active doses of oxycodone doubled latency of participants to withdraw their 
hand from 4° water (p < 0.001, Figure 2: Upper Panel) and latency to report feeling pain (p 
< 0.001), while significantly decreasing self-reported “Bothersomeness” of the pain (p < 
0.01). These ratings did not vary as a function of PIO maintenance dose.
Physiological Effects—The average pupil diameter, heart rate and breaths per minute 
decreased significantly as the session progressed (Time: p < 0.01, p < 0.05, p < 0.01, 
respectively). However, no influence of PIO, or PIO x Time interactions were found.
Pharmacokinetic Measures—Mean plasma oxycodone levels significantly increased as 
function of Time (p < 0.001), but no effects of PIO or interactions were found (Figure 2, 
Lower Panel). Analysis of plasma samples also revealed that significantly higher levels of 
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plasma PIO were achieved following active PIO maintenance periods vs placebo periods 
(Shown in Table 2, p < 0.01).
Discussion
The current study sought to determine whether pioglitazone, a PPARγ agonist and glial 
modulator, would alter the effects of oxycodone. In our sample of non-dependent 
recreational prescription opioid users, oral OXY produced typical mu opioid agonist effects, 
including miosis, decreased pain perception and respiratory rate, and mild cognitive 
impairment. Oxycodone also produced dose-dependent increases in reports of positive 
subjective effects with relatively minimal aversive effects. This subjective profile (which 
included mild GI upset) is similar to what has been previously reported by comparable 
participant samples (59, 60, 61). These data, once again, demonstrate the abuse potential 
common to most opioid analgesics, exemplifying the need to develop ways to alter these 
effects in order to deter recreational use that often leads to abuse and dependence (62). 
Unfortunately, our data revealed that an approximately 2-week period of PIO maintenance 
had no observable influence on the subjective, cognitive, analgesic, or physiological effects 
of OXY. Moreover, drug craving and recreational drug use did not vary as a function of PIO 
during the outpatient periods in between the testing sessions.
Pioglitazone dosing parameters (duration and mg amounts) were based on its clinical utility 
for treating diabetes, though these may not be related to its effects on glia (63). Although 
robust plasma concentrations of PIO were achieved, the lack of an observable PIO x OXY 
interaction may have been due to an inability of our dosing parameters to reduce levels of 
inflammatory markers. Unfortunately, the investigators did not include a measure of glial 
activation to test this hypothesis. The most relevant measurements of inflammatory markers 
would come from cerebrospinal fluid (CSF) but performing spinal taps on our participants 
would have significantly increased the risks associated with the study, and would have not 
been well-tolerated (64). Although measurements of inflammatory markers can also be 
found in plasma samples, previous research has demonstrated that plasma levels of 
inflammatory markers cannot be used to identify relative changes in the CSF (65).
The results of this study may also have varied if an opioid-dependent sample had been 
employed. According to the theory of opioid-induced glial activation and 
neuroinflammation; chronic opioid (ab)users may have higher tonic levels of glial activity 
upon which PIO could act (17, 29, 66). The use of a nondependent sample may also explain 
why the results of the current study are discrepant with preclinical studies on the efficacy of 
PIO for this purpose (39). Animal models may reflect a more severe state of opioid 
dependence.
In light of the present data, we must also consider the possibility that the opioid effects 
studies here may not be modulated by its actions on glial cells. As previously mentioned, 
there is an alternative body of literature arguing that opioids are immunosuppressive. 
According to this dissenting opinion, the logic behind the proposed clinical utility of an 
opioid + glia inhibitor combination is flawed. Therefore, the lack of an interaction observed 
in the current study would be consistent with this line of research (16, 67). Due to the 
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primary limitation of this study (i.e., lack of a measure of glial activity), what the current 
data adds to this debate is limited.
The primary limitation of this study (i.e., lack of a measure of glial activity) reflects the 
difficulty in performing this type of animal-to-human translational research. Specifically, no 
viable tools are available in clinical settings to confirm the mechanism by which glial 
modulators, such as ibudilast, minocycline, or pioglitazone, may be producing their effects. 
Although, within the current parameters, PIO failed to alter the subjective effects of OXY, it 
may be more effective in treating other forms of drug dependences. PPAR agonists have 
been shown to decrease ethanol consumption, ethanol-seeking and reduce withdrawal 
severity and susceptibility to stress-induced relapse in rodents (68, 69, 70).
Although PIO failed to alter the abuse liability of OXY under the current parameters, the 
interaction between glia and opioid receptors is not well understood. Other glial modulators 
acting through different mechanisms may show more promise. The prevalence and serious 
adverse consequences of opioid abuse make it imperative that we continue to investigate 
novel interventions such as this.
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Figure 1. 
Mean (± SEM) Visual Analog Scale (VAS) ratings of “Liked the Drug” and “Bad” drug 
effect, shown as a function of each preceding PIO maintenance condition (n=17).
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Figure 2. 
Mean (± SEM) amount of time participants (n=17) kept their hand immersed in cold water 
(4° C), and plasma oxycodone concentration (ng/ml), shown as a function of each preceding 
PIO maintenance condition.
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Table 1
Laboratory Session Events
Time points at which physiological, plasma, performance and subjective assessments were made throughout 
the testing session.
Time (min) Event
−30 Begin continuous physiological monitoring, pupils, subjective effects, CPT, performance battery
0 Pioglitazone or Placebo
15 Subjective effects, pupils,
30 Subjective effects, pupils, blood, CPT
45 OXY 0 mg, PO
60 Subjective effects, pupils,
75 Subjective effects, pupils, blood, CPT
90 OXY 10 mg, PO: Subjective effects, pupils
105 Subjective effects, pupils,
120 Subjective effects, pupils, blood
135 OXY 20 mg, PO (cumulative dose of 30 mg): Subjective effects, pupils
150 Subjective effects, pupils,
165 Subjective effects, pupils, blood, CPT
180 Subjective effects, pupils, blood, CPT,
195 Performance battery
210 Subjective effects, pupils, CPT
255 Subjective effects, pupils, performance battery, CPT
315 Subjective effects, pupils, blood, CPT, performance battery
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